Paclitaxel is used for: Ovarian carcinoma; Breast cancer; Lung cancer; Kaposi's sarcoma.
Recorded in the NepalDoc medicine catalog for Paclitaxel.
Paclitaxel is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
From the U.S. FDA-approved label for Paclitaxel. Full label: DailyMed.
Paclitaxel is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
From the U.S. FDA-approved label for Paclitaxel. Full label: DailyMed.
Do not substitute paclitaxel protein-bound particles for injectable suspension (albumin-bound) for other paclitaxel products. Extravasation: Closely monitor the infusion site for extravasation and infiltration. Metastatic Breast Cancer (MBC): Recommended dosage of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 260 mg/m2 intravenously over 30 minutes every 3 weeks.
Directions from the U.S. FDA-approved label for Paclitaxel — your doctor or pharmacist may advise differently.
Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is contraindicated in patients with: Baseline neutrophil counts of < 1,500 cells/mm 3 A history of severe hypersensitivity reactions to paclitaxel protein-bound particles for injectable suspension (albumin-bound). Neutrophil counts of < 1,500 cells/mm 3. Severe hypersensitivity reactions to paclitaxel.
Excerpt from the U.S. FDA-approved label for Paclitaxel. Talk to a pharmacist or doctor before use.
Sensory neuropathy occurs frequently and may require dose reduction or treatment interruption. Sepsis occurred in patients with or without neutropenia who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; interrupt paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine until sepsis resolves, and if neutropenia, until neutrophils are at least 1500 cells/mm 3, then resume treatment at reduced dose levels.
Warnings and precautions excerpt from the U.S. FDA-approved label for Paclitaxel — not a complete list. Talk to a pharmacist or doctor before use.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Excerpt from the U.S. FDA-approved label for Paclitaxel — not a complete list. Talk to a pharmacist or doctor about side effects.
13 brands · 6 makers in the NepalDoc catalog — see the full Paclitaxel guide →
Protect from bright light.
Storage information from the U.S. FDA-approved label for Paclitaxel.
What is Mitotax?
Mitotax 250mg/ml Injection is a Paclitaxel medicine made by Dr. Reddy's Laboratories. It comes as 250mg/ml Injection.
What is Mitotax used for?
Paclitaxel is used for Ovarian carcinoma, Breast cancer, Lung cancer, Kaposi's sarcoma.
What is the generic name of Mitotax?
The generic name of Mitotax is Paclitaxel.
Which brands of Paclitaxel are available in Nepal?
13 brands of Paclitaxel are listed in the NepalDoc catalog, from 6 makers — including C-Celtax 260MG/43.3ML Injection, Intaxel 260mg Tablet, Mitotax 100mg/ml Injection, Paclitax 100mg Injection, Paclitax 260mg Injection, Paclitax 30mg Injection.
What are the side effects of Paclitaxel?
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
